Xonef, eye drops 0.5% 5 ml

Csonef is a cardioselective beta1-adrenoblocker without intrinsic sympathomimetic activity. It has weak membrane stabilizing activity. It has hypotensive effect associated with reduction of cardiac output and decrease of sympathetic stimulation of peripheral vessels.

When used in therapeutic doses it does not have cardiodepressant effect, does not affect glucose metabolism, does not decrease the bronchodilator effect of beta-adrenomimetics and does not cause delay of sodium ions in the body. It works for a long time.

When used topically in the form of eye drops it reduces the increased intraocular pressure. The resorptive effect is expressed slightly.

Indications

Chronic open angle glaucoma,
increased intraocular pressure,
condition after laser trabeculoplasty.

Pharmacological effect

Xonef is a cardioselective beta1-blocker without intrinsic sympathomimetic activity. Has weak membrane stabilizing activity. It has a hypotensive effect associated with a decrease in cardiac output and a decrease in sympathetic stimulation of peripheral vessels.

When used in therapeutic doses, it does not have a cardiodepressive effect, does not affect glucose metabolism, does not reduce the bronchodilatory effect of beta-adrenergic agonists, and does not cause sodium ion retention in the body. Lasts for a long time.

When applied topically in the form of eye drops, it reduces elevated intraocular pressure. The resorptive effect is slightly expressed.

Special instructions

Prescribe the drug with caution to patients:

with diabetes mellitus, since beta-blockers may mask the symptoms of acute hypoglycemia.
with thyrotoxicosis, because beta blockers may mask symptoms of thyrotoxicosis (eg, tachycardia). In patients with suspected thyrotoxicosis, beta-blockers should not be abruptly discontinued, because this may cause increased symptoms.

It should be borne in mind that beta-blockers can cause symptoms similar to those of myasthenia gravis (diplopia, ptosis, general weakness).

patients with severe dysfunction of the respiratory system. Despite the fact that clinical studies have shown no effect of betaxolol in ophthalmic dosage form on respiratory function, the possibility of hypersensitivity to the drug cannot be excluded.
with caution in patients with Raynaud’s syndrome or pheochromocytoma.

Before elective surgery, beta-blockers should be gradually withdrawn 48 hours before general anesthesia, because during general anesthesia they can reduce the sensitivity of the myocardium to sympathetic stimulation.

Patients treated with beta-blockers may have a history of atopy or anaphylactic reactions. If repeated hypersensitivity reactions occur, such patients may not be sensitive to the usual doses of epinephrine (adrenaline) needed to relieve anaphylaxis.

When instilled into the eyes, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects may occur as with systemic use. Cases of severe respiratory and cardiovascular disorders have been described, including fatal bronchospasm in patients with bronchial asthma and death from heart failure.

Xonef has minimal effects on blood pressure and heart rate. However, caution should be exercised when prescribing the drug to patients with 1st degree AV block and mild to moderate heart failure. Treatment with Xonef should be stopped immediately when the first symptoms of decompensation in the cardiovascular system appear.

Xonef contains the preservative benzalkonium chloride, which can deposit on soft contact lenses and have a toxic effect on eye tissue. Therefore, patients wearing contact lenses should remove them before using drops and put them back no earlier than 20 minutes after instillation.

Impact on the ability to drive vehicles and operate machinery

If, after using the drops, the clarity of vision in patients is temporarily reduced, until it is restored, it is not recommended to drive vehicles or engage in activities that require increased attention and reaction.

Active ingredient

Betaxolol

Composition

1 ml eye drops contains:

active ingredient:

betaxolol 5 mg (as betaxolol hydrochloride),

excipients:

benzalkonium chloride;

hypromellose;

sodium chloride;

sodium hydroxide;

disodium edetate;

water for injections

Pregnancy

There is no sufficient experience with the use of the drug Xonef during pregnancy and lactation.

The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the expected benefit to the mother outweighs the potential risk to the fetus or child.

Use in children

Contraindicated for children and adolescents under 18 years of age.

Contraindications

hypersensitivity to the components of the drug;
sinus bradycardia;
AV block II and III degrees;
severe heart failure;
cardiogenic shock;
arterial hypotension;
children under 18 years of age.

The drug should be used with caution in case of thyrotoxicosis, myasthenia gravis, diabetes mellitus, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis.

Side Effects

From the side of the organ of vision: often – short-term discomfort in the eyes after instillation, lacrimation; in some cases – decreased sensitivity of the cornea, redness of the eyes, pinpoint keratitis, photophobia, anisocoria, photophobia, itching, feeling of “dry” eyes, allergic reactions.

Systemic side effects are rare:

From the central nervous system: dizziness, nausea, drowsiness, insomnia, headache, depression, increased symptoms of myasthenia gravis.

From the cardiovascular system: bradycardia, cardiac conduction disturbances and heart failure.

From the respiratory system: dyspnea, bronchospasm, bronchial asthma, respiratory failure.

Interaction

With the simultaneous use of Xonef and beta-blockers for oral administration, the risk of side effects (both local and systemic) increases due to an additive effect (therefore, patients receiving this combination of drugs should be under medical supervision).

When Xonef is used in combination with drugs that deplete catecholamines (such as reserpine), a decrease in blood pressure and bradycardia may occur.

With the simultaneous administration of muscle relaxants and hypoglycemic agents, an increase in their effect may be observed.

When used together with sympathomimetics, their vasoconstrictor effect is enhanced.

Caution should be exercised when using Xonef together with psychotropic drugs due to the possible enhancement of their effect.

Overdose

If excess amounts of the drug get into your eyes, rinse your eyes with warm water.

Symptoms: with an overdose of beta1-blockers, a decrease in blood pressure, bradycardia, and acute heart failure may be observed.

Treatment: carry out symptomatic therapy.

Storage conditions

In a place protected from light, at a temperature not exceeding 30 °C (do not freeze)

Shelf life

2 years

Manufacturer

Sentiss Pharma Pvt.Ltd, India